Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 12:44 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 889–912 of 1,054 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Sensitive Skin Clear all

Conditions: Psoriasis, Atopic Dermatitis
Interventions: BMX-010, Placebo; Drug
Lead sponsor: BioMimetix JV, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 139 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 10
States / cities: Encino, California • Denver, Colorado • Englewood, Colorado + 7 more

Conditions: Hookworm Infection, Allergy
Interventions: Na-ASP-2 Skin Test Reagent; Biological
Lead sponsor: Albert B. Sabin Vaccine Institute; Other
Eligibility: 18 Years to 45 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Toxic Epidermal Necrolysis
Interventions: Isotretinoin, Placebo; Drug · Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 69 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Atopic Dermatitis
Interventions: Altabax (R), Vehicle and Locoid lipocream (R); Drug
Lead sponsor: St. Luke's-Roosevelt Hospital Center; Other
Eligibility: 9 Months to 17 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 3
States / cities: New York, New York

Conditions: Atopic Dermatitis
Interventions: Photocil for Atopic Dermatitis, Placebo - Sunscreen (SPF 2); Drug · Other
Lead sponsor: Applied Biology, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Atopic Dermatitis
Interventions: Pimecrolimus; Drug
Lead sponsor: Novartis; Industry
Eligibility: 2 Years to 17 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 0
States / cities: Not listed

Conditions: Solid Tumor
Interventions: Rilvegostomig, Volrustomig, Sabestomig, Pembrolizumab, AZD9592, AZD9592 + Rilvegostomig, AZD9592 + Volrustomig, AZD9592 + Sabestomig, AZD9592 + Pembrolizumab; Biological · Combination Product
Lead sponsor: Presage Biosciences; Industry
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2031
U.S. locations: 9
States / cities: Shreveport, Louisiana • The Bronx, New York • Chapel Hill, North Carolina + 5 more

Conditions: Dermatitis, Atopic
Interventions: Dupilumab, JNJ-95475939, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 256 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 13
States / cities: Fountain Valley, California • Los Angeles, California • Alpharetta, Georgia + 10 more

Conditions: Atopic Dermatitis, Eczema
Interventions: SkinTracker Mobile App; Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 13 Years and older
Enrollment: 11 participants
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Atopic Dermatitis
Interventions: Not listed
Lead sponsor: National Jewish Health; Other
Eligibility: 18 Years to 65 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Atopic Dermatitis
Interventions: Ruxolitinib cream, Vehicle; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 12 Years to 70 Years
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Culver City, California

Conditions: Atopic Dermatitis
Interventions: Placebo for Upadacitinib, Upadacitinib; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 12 Years to 75 Years
Enrollment: 912 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 58
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Bakersfield, California + 50 more

Conditions: Atopic Dermatitis, Eczema
Interventions: Pre-Treatment with Dial liquid antibacterial soap, Control; Drug · Other
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years to 80 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: San Diego, California

Conditions: Hereditary Angioedema, Hereditary Angioedema Type I, Hereditary Angioedema Type II, Hereditary Angioedema Types I and II, Hereditary Angioedema Attack, Hereditary Angioedema With C1 Esterase Inhibitor Deficiency, Hereditary Angioedema - Type 1, Hereditary Angioedema - Type 2, C1 Esterase Inhibitor Deficiency, C1 Inhibitor Deficiency
Interventions: Deucrictibant, Placebo; Drug
Lead sponsor: Pharvaris Netherlands B.V.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 8
States / cities: Birmingham, Alabama • Paradise Valley, Arizona • San Diego, California + 5 more

Conditions: Allergy Skin, Allergic Skin Reaction
Interventions: ColActivePlus Collagen Matrix Dressing; Device
Lead sponsor: Covalon Technologies Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Torrance, California

Conditions: Hereditary Angioedema
Interventions: rhC1INH; Drug
Lead sponsor: Pharming Technologies B.V.; Industry
Eligibility: 13 Years and older
Enrollment: 152 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Fairfax, Virginia

Conditions: Hereditary Angioedema (HAE), Hereditary Angioedema - Type 1, Hereditary Angioedema - Type 2, HAE
Interventions: ADX-324 Dose Level 1, ADX-324 Dose Level 2; Drug
Lead sponsor: ADARx Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 15
States / cities: Litchfield Park, Arizona • Little Rock, Arkansas • San Diego, California + 12 more

Conditions: Dermatitis Atopic
Interventions: Lunsekimig, Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 23
States / cities: Encino, California • Sacramento, California • Thousand Oaks, California + 19 more

Conditions: Allergic Contact Dermatitis (ACD)
Interventions: Dermabond PRINEO, Silk fibroin; Device
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years and older
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Allergic Rhinitis
Interventions: saline with 1mg/ml Histamine base, diluent, saline with HSA--phenol; Drug
Lead sponsor: Bryan Martin, DO; Other
Eligibility: 18 Years to 60 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Photoallergy
Interventions: SPF 50 Y65 110 (BAY987519), SPF 50 Y51 002 (BAY987519), SPF 15 V27 104 (BAY987519), Sodium chloride [NaCl]; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Pinellas Park, Florida

Conditions: Atopic Dermatitis, Pruritus
Interventions: Levocetirizine dihydrochloride (Xyzal), placebo; Drug
Lead sponsor: Derm Research, PLLC; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Louisville, Kentucky

Conditions: Atopic Dermatitis
Interventions: Ruxolitinib, Vehicle Cream; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 159 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 20
States / cities: Birmingham, Alabama • Phoenix, Arizona • Denver, Colorado + 17 more

Conditions: Dermatitis, Atopic
Interventions: LY3454738, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 128 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2021
U.S. locations: 19
States / cities: Anniston, Alabama • North Little Rock, Arkansas • Rogers, Arkansas + 16 more

Search by objective public record fields.

Topical Application of BMX-010 in Subjects With Atopic Dermatitis and Plaque Psoriasis

Development of a Skin Test for the Na-ASP-2 Hookworm Antigen

Evaluating the Effect of Isotretinoin in Regulatory T-cell Function in Adverse Cutaneous Drug Eruptions (ACDEs): A Pilot Study

Trial of Treatment of Atopic Dermatitis With Concurrent Altabax® and Topical Low-Potency Corticosteroids Versus Low-Potency Corticosteroid Mono-therapy

Photocil (Topical) for the Treatment of Atopic Dermatitis

Comparison of Pimecrolimus Cream 1% Twice-Daily to Once-Daily Dosing in the Management of Atopic Dermatitis in Pediatric Subjects

Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer Therapies

A Study of JNJ-95475939 in the Treatment of Participants With Moderate to Severe Atopic Dermatitis (AD)

Skin Tracker: A Mobile Health App to Monitor Skin Disease Activity and Treatment Use

Effects of Pimecrolimus on Skin Biopsy Ex-plants From Patients With Atopic Dermatitis

Ruxolitinib Cream in Participants With Facial and/or Neck Atopic Dermatitis Involvement

Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema)

Examination of Whether Host Preconditioning Modifies Short-term Transplant Survival

Dose-ranging Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedema

SPT for Sensitization of Collagen Dressing

Patient Registry to Evaluate the Real-world Safety of Ruconest®

Phase 3 Extension Study of ADX-324 in Participants With Hereditary Angioedema (HAE)

A Study to Investigate the Efficacy and Safety of Subcutaneous Lunsekimig (SAR443765) Compared With Placebo in Adult Participants With Moderate-to-severe Atopic Dermatitis

Use of Silk Fibroin Dressings in Primary Total Hip Arthroplasty

Effect of HSA or Saline Diluent on Immunotherapy Extract Stability as Determined by Graded ID Skin Tests

To Test for Photo Allergy Reaction of Sunscreens

Management of Pruritus With Xyzal in Atopic Dermatitis

A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children and Adolescents (6 to <18 Years Old) With Moderate Atopic Dermatitis

A Study of LY3454738 in Healthy Participants and Participants With Atopic Dermatitis